October 9 - 12, 2012
Building 10 & Natcher Conference Center
- General Schedule of Events
- Opening Plenary Session
- Concurrent Symposia Sessions
- Poster Sessions
- National Graduate Student Research Conference
- FARE Award Ceremony
- Special Exhibits on Resources for Intramural Research
- TSA Research Festival Exhibit Show
- Clinical Center Tours
- Research Festival Committees
- Past Research Festivals
Therapeutically targeting glypican-3 via a novel conformation-specific single-domain antibody in hepatocellular carcinoma
| Friday, November 08, 2013 — Poster Session IV | |||
|---|---|---|---|
2:00 p.m. – 4:00 p.m. |
FAES Academic Center (Upper-Level Terrace) |
NCI |
IMMUNO-5 |
Authors
- Mingq Feng
- Wei Gao
- Ruoqi Wang
- Weiza Chen
- Yan-G Man
- Willi Figg
- Xin W Wang
- Dimit Dimitrov
- Mitch Ho
Abstract
Glypican-3 (GPC3) has emerged as a candidate therapeutic target in hepatocellular carcinoma (HCC), but the oncogenic role of GPC3 in HCC is poorly understood. Here, we report a novel human heavy chain variable domain antibody (HN3) with high affinity (KD = 0.6 nM) for cell surface-associated GPC3 molecules. The human antibody recognized a conformational epitope that requires both the amino and carboxy terminal domains of GPC3. HN3 inhibited proliferation of GPC3-positive cells and exhibited significant HCC xenograft tumor growth inhibition in nude mice. The underlying mechanism of HN3 action may involve cell cycle arrest at G1 phase through yap signaling. This study suggests a novel mechanism for GPC3-targeted cancer therapy.
